YourChoice Therapeutics, a biotech company based in California, has reported promising safety data from an early-stage ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Icotrokinra is designed to selectively block the IL-23 receptor, which drives inflammation in plaque psoriasis and ...

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized ...

Chimeric antigen receptor T cell therapy has reshaped expectations for treating hematological malignancies and is now ...

Obefazimod’s strong Phase 3 induction data positions Abivax as leading UC contender with novel mechanism and favorable safety ...

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.